Published in Cancer Weekly, May 5th, 1997
The agreement expands Phase I clinical trials currently in progress at the NCI. Under the terms of the CRADA, Genzyme Transgenics has licensing rights to the idiotypic vaccines being developed in collaboration with the NCI.
Idiotypic vaccines contain proteins derived from individual patient tumors or from specific types of tumors. In the Phase I trials, the vaccines are...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.